IFI44L and neoplasm: Based on TCGA-HNSC data, IFI44L is differentially expressed in subjects with different clinical parameters, including downregulated in male subjects (Fig. S2A), downregulated in subjects with tumor (Fig. S2B), downregulated in subjects with progression after therapy (Fig. S2C), and downregulated in higher tumor stages (not significantly, Fig. S2D).